Teva Specialty & Biosimilar Product Pipeline

by development stage - October 2021


Teva’s Global R&D organization helps propel the company’s mission to be a global leader in generics and biopharmaceuticals. From early development to commercial launch of small molecules, novel biologics and biosimilars, our uniquely integrated “One Teva” drug development model combines our strength in generics with our knowledge of innovative drug development.  We understand the many ways that health impacts people’s lives, and will continue to invest in new breakthrough treatments, offer innovative solutions, and find new ways to extend and expand patient care beyond medicine.

Technology Platforms:

Novel Biologics
Small Molecules
Digital Respiratory
Biosimilars

Under Regulatory Review

Biosimilar to Humira®
(adalimumab) 01

Risperidone LAI Schizophrenia

Biosimilar to Lucentis® (ranibizumab) 05

Pre Submission

Digihaler®
(budesonide and formoterol
fumarate dihydrate)
(EU)

QVAR® Digihaler® 
(beclomethasone dipropionate HFA)
(US)

Phase 3

Fasinumab 03
Osteoarthritic Pain

Deutetrabenazine 04
Dyskinesia in Cerebral Palsy

Biosimilar to Prolia® (denosumab)

Biosimilar to Stelara® (Ustekinumab) 01

Biosimilar to Xolair® (omalizumab)

Phase 2

Fremanezumab 02
Fibromyalgia

TEV-48574
Respiratory

TEV-53275
Respiratory

Deutetrabenazine 04 “additional indication”

Phase 1

Fremanezumab 02
Status Migrainosus

TV-44749
Schizophrenia

TEV-53408
Gastrointestinal

Pre-clinical

TEV-56278
Oncology

TEV-56192
Respiratory

TEV-56279
Pain

TV-48438
Schizophrenia

TEV-56248
Respiratory

TEV-56285

TEV-54142

TEV-56194

TEV-56191

TEV-56261

TEV-56282 01

TEV-56283 01

TEV-56284 01

Novel Biologics
Small Molecules
Digital Respiratory
Biosimilars

Download a PDF version of Teva Specialty and Biosimilar Product Pipeline

Download PDF

Teva specialty pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.
*Visit https://www.tevausa.com/our-products/article-pages/Specialty-Medicines-List/ for full prescribing information for these products in the US.

Pipeline is current as of October 27, 2021

  1. Back to contents.

    In collaboration with Alvotech in US.

  2. Back to contents.

    These uses are investigational. Fremanezumab is approved in the United States for another indication as AJOVY® (fremanezumab-vfrm) injection*.

  3. Back to contents.

    In collaboration with Regeneron.

  4. Back to contents.

    These uses are investigational. Deutetrabenazine is approved in the United States for other indications as AUSTEDO® (deutetrabenazine) tablets*.

  5. Back to contents.

    In collaboration with BioEq in Europe, Canada.